www.rsc.org/obc

Selective synthesis of *C*-arylglycosides *via* Cp*RuCl-catalyzed partially intramolecular cyclotrimerizations of *C*-alkynylglycosides

Yoshihiko Yamamoto,
*" Tomoaki Saigoku," Hisao Nishiyama," Takashige Ohgai
b b and Kenji Itoh b

- ^a Department of Applied Chemistry, Graduate School of Engineering, Nagoya University, Chikusa, Nagoya, 464-8603, Japan. E-mail: yamamoto@apchem.nagoya-u.ac.jp; Fax: 81 52 789 3209; Tel: 81 52 789 3337
- ^b Department of Molecular Design and Engineering, Graduate School of Engineering, Nagoya University, Chikusa, Nagoya, 464-8603, Japan

Received 4th March 2005, Accepted 21st March 2005 First published as an Advance Article on the web 7th April 2005

In the presence of catalytic amounts of Cp*RuCl(cod), the partially intramolecular cyclotrimerizations of various *C*-alkynylglycosides and *C*-diynylglycosides proceeded at ambient temperature to afford *C*-arylglycosides.

Introduction

The synthesis of *C*-glycosides, in which the glycosidic oxygen is replaced by a carbon atom, has been an area of intense study in bioorganic and synthetic chemistry.¹ This is because the stability of *C*-glycosides towards the enzymatic and chemical hydrolysis renders them unique applicability. For example, the enzymatically stable *C*-glycosides are potent enzyme inhibitors and substrates for carbohydrate-binding proteins.¹

Frequently encountered *C*-glycoside motifs in nature are *C*-arylglycosides. Owing to their significant biological activities, the synthesis of naturally occurring *C*-arylglycosides such as anthracyclinone *C*-glycosides, gilvocarcins, or kidamycins has been an important subject in synthetic organic chemistry.²⁻⁵ *C*-Arylglycosides are generally obtained by the direct arylation of appropriate carbohydrate substrates,² but the control of regiochemistry is a crucial problem when a multiply substituted aromatic precursor is employed for this purpose. To address this issue, alternative methods of directly constructing a glycosylated benzene skeleton have recently been developed by exploiting benzannulation or cycloaddition strategy.⁶

In this context, the [2 + 2 + 2] cycloaddition of α,ω -diynes with *C*-alkynylglycosides might be a promising approach to obtain C-arylglycosides in a convergent and atom-economical manner. McDonald and co-workers realized this method for the first time as shown in Scheme 1.⁷ In this example, they use Wilkinson catalyst, RhCl(PPh₃)₃, in EtOH at 78 °C to achieve the cycloaddition of a diketodiyne with protected alkynylglycals. Although the anthraquinone *C*-glycoside structure relevant to vienomycinone B was elegantly assembled in a single operation, relatively high catalyst loadings (20 mol%) are required and the isolated yields were lower than 60%. In addition, the scope

RO RO^{+} RO^{+}

Scheme 1

of the [2 + 2 + 2] cycloaddition strategy has remained largely unexplored with respect to both diyne and *C*-alkynylglycoside substrates. With these backgrounds in mind, we recently applied our ruthenium catalysis⁸ to the [2 + 2 + 2] cycloaddition of *C*-alkynylglycosides with diynes leading to bicyclic *C*arylglycosides.⁹ Herein, we report the full details of the study on the *C*-arylglycoside synthesis by means of the Ru(II)-catalyzed partially intramolecular cyclotrimerizations.

Results and discussion

Optimization of Cp*RuCl-catalyzed cycloaddition with C-alkynylglycoside and scope of α , ω -diyne substrate

At the outset, C-alkynylglycoside 1a, which was readily prepared from commercially available D-glucal and bis(trimethylsilyl)acetylene according to the procedure of Isobe and co-workers,10 was subjected to the ruthenium-catalyzed cycloaddition with dimethyl dipropargylmalonate 2a (Scheme 2). Our previously reported protocol,8 however, gave rise to considerable amounts of the diyne dimer. In order to suppress the dimerization, a solution of 2a in dry degassed 1,2-dichloroethane (DCE) was added to a DCE solution containing 5 mol% Cp*RuCl(cod) $(Cp^* = \eta^5 - C_5 Me_5, cod = 1,5$ -cyclooctadiene) and 2 equiv. of 1a over 2.5 h via syringe pump at ambient temperature, and the solution was further stirred for 24 h (method A). Purification with silica gel chromatography afforded the desired C-arylglycoside 3aa in 50% yield together with the recovered 1a (16%) and 2a (40%) (Table 1, run 1). The yield was successfully improved to 85% by adding the solution of 2a and 2 equiv of 1a to the catalyst solution (method B, run 2). In this case, most of unreacted 1a was recovered intact after chromatography. The prolonged syringe pump addition over 5 h realized the highest yield of 93% (method C, run 3). With a reduced amount of 1a (1.5 equiv), the reaction was not completed even after overnight stirring, and the yield was lowered to 62% (method D, run 4).





Table 1 Ru(II)-catalyzed cycloaddition of 1a with 2a-c

Run	Diyne, X	Method ^a	3, yield	Recovered 1a
1	2a, C(CO ₂ Me) ₂	A	3aa , 50% ^b	16%
2	2a, C(CO ₂ Me) ₂	B	3aa , 85%	49%
3	2a, C(CO ₂ Me) ₂	C	3aa , 93%	32%
4	2a, C(CO ₂ Me) ₂	D	3aa , 62% ^b	50%
5	2b, NTs	C	3ab , 89%	34%
6	2c, O	C	3ac , 46%	40%

^{*a*} A: To a solution of 5 mol% Cp*RuCl(cod) and **1a** (2 equiv) was added a solution of **2** over 2.5 h, and the solution was stirred at rt for 24 h. B: To a solution of 5 mol% Cp*RuCl(cod) was added a solution of **2** and **1a** (2 equiv) over 2.5 h, and the solution was stirred at rt for 1.5 h. C: To a solution of 5 mol% Cp*RuCl(cod) (10 mol% for run 6) was added a solution of **2** and **1a** (2 equiv.) over 5 h (10 h for run 6). D: To a solution of 5 mol% Cp*RuCl(cod) was stirred overnight. ^{*b*} The diyne **2a** was recovered in 40% (run 1) and 30% (run 4).

Under the optimal reaction conditions (method C), the generality of the present protocol was examined with respect to the diyne substrate. The tosylamide derivative **2b** was allowed to react with **1a** in the same manner with **2a** to afford **3ab** in 89% yield (Table 1, run 5). On the other hand, the less reactive propargyl ether **2c** required the increased catalyst loading of 10 mol% as well as the longer dropping time of 10 h (run 6). The desired product **3ac** was obtained in 46% yield.

In addition to the above 1,6-divnes, 1,7-divnes, 1,2-bis-(propiolyl)benzene 4a and its derivative 4b, could be used for the Ru(II)-catalyzed cycloaddition. Whereas the transition-metalcatalyzed cycloaddition of 1,2-bis(propiolyl)benzene derivatives with monoynes were reported to give anthraquinones,^{7,11} previous Ni-, Co-, or Rh-based catalyses seem less suitable for C-alkynylglycosides. They require sub-stoichiometric amounts of a precatalyst and/or a reaction temperature above 60 °C, and the product yields were not higher than 80%. On the other hand, the ruthenium-catalyzed reaction proceeded at room temperature with catalyst loadings of 1-10 mol% to afford the desired products in 33-92% yields.12 Indeed, in the presence of 5 mol% Cp*RuCl(cod), the reaction of 4a with 1a successfully proceeded at ambient temperature to furnish anthraquinone Cglycoside 5aa in 87% yield (Scheme 3). Whereas internal diyne 4b required an increased catalyst loading of 10 mol%, the desired C-glycosylquinone 5ab was also obtained in a similar high yield.



Scope of C-alkynylglycoside

Next we examined the generality of the present method with respect to the *C*-alkynylglycoside. The ruthenium catalysis proved to be applicable to various types of *C*-alkynylglycosides as summarized in Table 2. The reaction of diyne **2a** with *C*-alkynylglycoside **1b** and **1c** derived from D-galactal and L-rhamnal gave the corresponding *C*-arylglycosides **3ba** and **3ca** in 90 and 80% yields, respectively. In addition to the unsaturated carbohydrate precursors **1a–c**, D-glucose derivative **1d**¹³

Table 2Synthesis of C-aryglycosides from C-alkynylglycosides 1b-gand diynes 2a.^a



^{*a*} To a solution of 5 mol% Cp*RuCl(cod) was added a solution of **2a** and **1** (2 equiv.) over 5 h *via* syringe pump at room temperature.

underwent cycloaddition with 2a to uneventfully give 3da in 89% yield. More significantly, the ruthenium catalysis well tolerates hydroxy groups. Thus, unprotected carbohydrates 1e and $1f^{14}$ were allowed to react with 2a under the same reaction conditions to afford 3ea and 3fa in 77 and 74% yields, respectively. We also examined deoxy-D-ribose derivative $1g^{15}$ as an alkynylated furanose, because *C*-nucleosides have been reported to exhibit antiviral, antitumor, and anticancer activity, and nonpolar *C*-arylnucleosides were used as probes of noncovalent interactions in nucleic acids.¹⁶ As a result, the same procedure with those for the above pyranose derivatives gave rise to the expected arylribose 3ga in 90% yield.

Regioselectivity of the cycloaddition of unsymmetrical diynes and regioselective synthesis of bis(glycosyl)benzenes

Previously, we found that the Cp*RuCl-catalyzed [2 + 2 + 2] cycloaddition of unsymmetrical diynes bearing a terminal substituent with terminal monoalkynes selectively gave *meta*-substituted benzenes.⁸ In accordance with this finding, unsymmetrical 1,6-diyne 6 underwent regioselective cycloaddition with *C*-alkynylglycoside 1a in the presence of 5 mol% Cp*RuCl(cod) at room temperature for 5 h (Scheme 4). As a consequence, tetra-substituted benzene 7 was obtained in 78% yield with the good regioselectivity of *meta*: *ortho* = 95 : 5.

In the next step, we prepared unsymmetrical C-glycosyldiyne **8a** and examined its cycloaddition with terminal alkynes



Scheme 4

(Scheme 5). In a similar manner as above, **8a** was added to the DCE solution containing 5 mol% Cp*RuCl(cod) and 2 equiv. of 1-hexyne at room temperature over 5 h. The desired cycloadduct **9a** was obtained in 83% yield with the good isomer ratio of *meta* : *ortho* = 94 : 6. On the other hand, the use of ethynylbenzene required an increased catalyst loading of 10 mol%, and led to the formation of **9b** in 80% with the somewhat diminished regioselectivity of *meta* : *ortho* = 87 : 13.



Taking advantage of the useful regioselectivity demonstrated in the above examples, a bicyclic benzene possessing two Cglycosyl groups, which are placed in mutually meta-positions, might be synthesized by the combination of C-glycosyldiynes 8 and C-alkynylglycosides 1. Whereas oligosaccharides have found significant medicinal applications, their instability toward enzymatic hydrolysis is a crucial problem. Thus, the synthesis of stable O-saccharide mimics, C-disaccharides or pseudo-Cdisaccharides, in which the two sugar rings are connected by several carbon atoms, has became more and more important in glycobiology.¹⁷ Among those C-disaccharides, bis(Cglycosyl)benzenes are an attractive target, because such a benzene-bridged C-disaccharide motif has been found in the naturally occurring antibiotic kidamycin and its analogues.⁵ With these in mind, we attempted the cycloaddition of 8a-c with **1a** as outlined in Scheme 6. In the presence of 10 mol% Cp*RuCl(cod), C-glycosyldiyne 8a was allowed to react with 1a under the same reaction conditions. Gratifyingly, only the desired meta-substituted indan C-disaccharide 10aa was formed in 73% yield. In the same manner, tosylamide- or ether-tethered Cglycosyldiynes 8b or 8c afforded the corresponding isoindoline 10ab and phthalan 10ac in 70 and 86% yields, respectively.

The present method can be essentially extended to various combinations of C-glycosyldiynes and C-alkynylglycoside. In fact, the reaction of 1g and 8a led to the formation of indan



derivative 10ga possessing both the furanose and the pyranose moieties in 70% yield.

In addition to the *meta*-bis(*C*-glycosyl)benzenes, the corresponding *para*-isomers were also selectively synthesized from bis(C-glycosyl)diynes **11** and gaseous acetylene (Scheme 7). The reactions of these sterically demanding diynes requires 20 mol% catalyst loadings. Under an acetylene atmosphere, malonate-derived diyne **11a** was added to the catalyst solution by syringe pump over 5 h at ambient temperature. The desired **12a** was obtained in 64% yield. The reaction of ether-tethered diyne **11b** gave **12b** in a higher yield of 81%. It is noteworthy that the ether-tethered diynes **8c** and **11b** gave better results than the corresponding malonate analogues **8a** or **11a**, although the diynes bearing a quaternary center generally show higher cyclization ability owing to the kinetic Thorpe–Ingold effect.¹⁸



Synthesis of novel sugar-amino acid conjugate molecules

Recently, synthetic sugar amino acids have received increasing attention as mimics of natural ones found in glycopeptides.¹⁹ In particular, sugar amino acids, in which the sugar unit was

 Table 3
 Synthesis of C-aryglycoside amino acids from C-alkynylglycoside 1a and diynes 13.^a



^{*a*} To a solution of 10 mol% Cp*RuCl(cod) was added a solution of **13** and **1a** (2 equiv.) over 5 h *via* syringe pump at room temperature.

connected with amino acid moiety by an all-carbon tether, are of significance because they are metabolitically resistant analogues of natural sugar amino acids that exhibit inhibitory activity toward glycosidases. In this respect, we finally explored the synthesis of a novel type of sugar-amino acid conjugate molecule via our Ru(II)-catalyzed cycloaddition technique. Previously, Kotha and co-workers developed the [2 + 2 + 2] cycloaddition of amino acid-tethered diyne derivatives with monoalkynes by means of rhodium and cobalt catalysis, leading to constrained phenylalanine analogues in various yields.²⁰ However, the synthesis of sugar amino acids through the [2 + 2 + 2]cycloaddition of diynes containing an amino acid moiety with C-alkynylglycosides have remained unexplored (Scheme 8). In our hands, The N,N-dipropargylated L-glutamic acid diethyl ester 13a was allowed to react with 1a in the presence of 10 mol% Cp*RuCl(cod) to give the expected sugar amino acid 14a in 83% yield (Table 3). Similarly, L-phenylalanine and L-leucine analogues 14b and 14c were also obtained in 70 and 63% yields, respectively.



Conclusions

In conclusion, we successfully developed a general protocol to synthesize *C*-arylglycosides by means of the Cp*RuCl-catalyzed [2 + 2 + 2] cycloaddition of α, ω -diynes with *C*-alkynylglycosides under mild reaction conditions. The functional group compatibility of the ruthenium catalysis towards a wide variety of functional groups allows us to synthesize interesting *C*-arylglycosides including anthraquinone *C*-glycosides, bis(*C*-glycosyl)benzenes as well as *C*-arylglycoside amino acids.

Experimental

Flash chromatography was performed with a silica gel column (Cica silica gel 60N) eluted with mixed solvents [hexane-AcOEt]. ¹H and ¹³C NMR spectra were obtained for samples in CDCl₃ solution at 25 °C on a Varian Mercury 300 spectrometer. ¹H NMR chemical shifts are reported in δ units, in ppm relative to the singlet at 7.26 ppm for chloroform. Coupling constants are reported in Hz. Infrared spectra were recorded for CHCl₃ sample solutions in 0.2 mm path length sodium chloride cavity cells on a JASCO FT/IR-230 spectrometer. Mass spectra were recorded on a JEOL JMS700 mass spectrometer. Elemental analyses were performed by the Microanalytical Center of Kyoto University and Instrumental Analysis Facility of Nagoya University. Melting points were obtained on a Büchi B-540 apparatus. CH₂Cl₂ and 1,2-dichloroethane were dried over CaH₂ and distilled. Cp*RuCl(cod) was prepared according to the reported method.21

Representative procedure for Cp*RuCl-catalyzed synthesis of *C*arylglycosides: synthesis of *C*-arylglycoside 3aa from 1a and 2a

To a solution of Cp*RuCl(cod) (5.7 mg, 0.015 mmol) in dry degassed DCE (1 mL) was added a solution of 2a (67.4 mg, 0.32 mmol) and 1a (143.0 mg, 0.6 mmol) in DCE (4 mL) over 5 h via syringe pump at room temperature. The reaction mixture was concentrated *in vacuo* and the residue was purified by silica gel column flash chromatography (eluent, hexane : AcOEt = 6:1) to afford 3aa (132.8 mg, 93%) as a colorless solid: mp. 106.2–107.2 °C; $[a]^{25}_{D} = -27.8 (c = 0.05, CHCl_3);$ IR (CHCl₃) 1734, 1247 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.06 (s, 3 H), 2.08 (s, 3 H), 3.58 (s, 4 H), 3.73 (s, 3 H), 3.74 (s, 3 H), 3.84 (ddd, J = 6.6, 6.0, 3.0 Hz, 1 H), 4.08 (dd, J = 12.0,3.0 Hz, 1 H), 4.26 (dd, J = 12.0, 6.0 Hz, 1 H), 5.25–5.30 (m, 2 H), 5.96 (ddd, J = 10.2, 2.4, 1.8 Hz, 1 H), 6.14 (ddd, J = 10.2, 3.0, 1.5 Hz, 1 H), 7.18–7.19 (m, 2 H), 7.23 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.73, 20.99, 40.23, 40.41, 52.86, 60.24, 62.70, 64.86, 69.22, 73.40, 123.53, 123.97, 124.57, 126.61, 131.43, 137.57, 139.77, 140.06, 170.08, 170.41, 171.60; MS (FAB): m/z (%): 445 (14) [M⁺ – H], 385 (35) [M⁺ – H – HOAc], 327 (100) $[M^+ - H - 2OAc]$; EA calcd (%) for C₂₃H₂₆O₉ (446.45): C 61.88, H 5.87; found: C 61.96, H 5.86.

3ab. Mp. 134.5–135.4 °C; $[a]_{25}^{25} = -39.2$ (c = 0.05, CHCl₃); IR (CHCl₃) 1737, 1235 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.05 (s, 3 H), 2.07 (s, 3 H), 2.40 (s, 3 H), 3.79 (ddd, J =6.3, 6.0, 3.0 Hz, 1 H), 4.06 (dd, J = 12.0, 3.0 Hz, 1 H), 4.25 (dd, J = 12.0, 6.0 Hz, 2 H), 4.61 (s, 4 H), 5.23–5.39 (m, 2 H), 5.97 (ddd, J = 10.2, 2.4, 1.5 Hz, 1 H), 6.11 (ddd, J = 10.2, 2.7, 1.2 Hz, 1 H), 7.17 (d, J = 7.8 Hz, 1 H), 7.21 (s, 1 H), 7.28 (d, J =7.8 Hz, 1 H), 7.31 (d, J = 8.4 Hz, 2 H), 7.76 (d, J = 8.4 Hz, 2 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.87, 21.11, 21.57, 53.51, 53.61, 62.69, 64.82, 69.60, 73.15, 121.96, 122.63, 124.95, 127.41, 127.48, 129.70, 131.15, 133.58, 136.09, 136.48, 138.80, 143.58, 170.18, 170.52; MS (FAB): m/z (%): 484 (100) [M⁺ – H], 366 (25) [M⁺ – H – 2OAc]; EA calcd (%) for C₂₅H₂₇NO₇S (485.88): C 61.84, H 5.60, N 2.88; found: C 61.71, H 5.60, N 2.82.

3ac. Mp. 53.3–54.1 °C; $[a]_{25}^{25} = -12.7$ (c = 0.53, CHCl₃); IR (CHCl₃) 1737, 1238 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.07 (s, 3 H), 2.09 (s, 3 H), 3.85 (ddd, J = 6.9, 6.0, 3.0 Hz, 1 H), 4.09 (dd, J = 12.0, 3.0 Hz, 1 H), 4.28 (dd, J = 12.0, 6.0 Hz, 2 H), 5.11 (s, 4 H), 5.27–5.34 (m, 2 H), 5.99 (ddd, J =10.5, 3.0, 2.1 Hz, 1 H), 6.17 (ddd, J = 10.5, 3.0, 1.5 Hz, 1 H), 7.23 (d, J = 7.5 Hz, 1 H), 7.29 (s, 1 H), 7.31 (dd, J =7.5, 1.5 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.87, 21.13, 62.79, 64.94, 69.42, 73.34, 73.40, 73.46, 120.40, 120.91, 124.91, 127.10, 131.37, 138.14, 139.17, 139.53, 170.22, 170.56; MS (FAB): m/z (%): 331 (100) [M⁺ – H], 273 (51) [M⁺ – OAc], 213 (79) [M⁺ – H – 2OAc]; EA calcd (%) for C₁₈H₂₀O₆ (332.35): C 65.05, H 6.07; found: C 65.00, H 6.07. **3ba.** Mp. 97.0–98.0 °C; $[a]_{25}^{25} = -176.1$ (c = 1.02, CHCl₃); IR (CHCl₃) 1733, 1247 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.01 (s, 3 H), 2.11 (s, 3 H), 3.59 (s, 4 H), 3.74 (s, 3 H), 3.75 (s, 3 H), 3.93 (ddd, J = 6.9, 6.0, 2.7 Hz, 1 H), 4.15 (dd, J = 11.5, 5.7 Hz, 1 H), 4.21 (dd, J = 11.5, 6.0 Hz, 1 H), 5.10 (dd, J = 5.1, 2.4 Hz, 1 H), 5.33–5.37 (m, 1 H), 6.17 (ddd, J = 10.2, 5.4, 2.4 Hz, 1 H), 6.37 (ddd, J = 10.2, 3.6, 0.6 Hz, 1 H), 7.18 (br s, 2 H), 7.21 (br s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.81, 21.00, 40.33, 40.52, 53.02, 60.36, 62.70, 63.75, 68.21, 73.63, 123.20, 123.53, 124.07, 126.55, 123.26, 137.10, 139.84, 140.15, 170.31, 170.37, 171.73; MS (FAB): m/z (%): 447 (75) [MH⁺], 387 (53) [M⁺ – OAc], 327 (100) [M⁺ – H – 2OAc]; EA calcd (%) for C₂₃H₂₆O₉ (446.45): C 61.88, H 5.87; found: C 61.84, H 5.90.

3ca. Oil; $[a]_{27}^{27} = -25.2$ (c = 1.06, CHCl₃); IR (CHCl₃) 1732, 1249 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 1.24 (d, J = 6.3 Hz, 3 H), 2.10 (s, 3 H), 3.59 (s, 2 H), 3.60 (s, 2 H), 3.75 (s, 6 H), 3.86 (quint, J = 6.3 Hz, 1 H), 5.00–5.04 (m, 1 H), 5.17 (dd, J = 4.5, 2.4 Hz, 1 H), 5.93 (ddd, J = 10.2, 3.3, 1.8 Hz, 1 H), 6.09 (ddd, J = 10.2, 2.7, 1.2 Hz, 1 H), 7.18–7.20 (m, 2 H), 7.22 (br s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 17.27, 21.25, 40.29, 40.48, 52.95, 60.35, 68.04, 69.67, 72.58, 123.60, 123.85, 124.02, 126.71, 132.18, 138.30, 139.66, 140.08, 170.50, 171.73; MS (FAB): m/z (%): 389 (64) [MH⁺], 329 (100) [M⁺ – OAc]; EA calcd (%) for C₂₁H₂₄O₇ (388.41): C 64.94, H 6.23; found: C 64.67, H 6.50.

3da. Mp. 62.0–63.2 °C; $[a]_{D}^{25} = -53.1$ (c = 0.05, CHCl₃); IR (CHCl₃) 1750, 1231 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 1.80 (s, 3 H), 2.00 (s, 3 H), 2.05 (s, 3 H), 2.08 (s, 3 H), 3.57 (s, 4 H), 3.73 (s, 3 H), 3.74 (s, 3 H), 3.81 (ddd, J = 9.9, 4.5, 2.1 Hz, 1 H), 4.13 (dd, J = 12.0, 2.1 Hz, 1 H), 4.27 (dd, J = 12.0, 4.8 Hz, 1 H), 4.36 (d, J = 9.9 Hz,1 H), 5.11 (t, J = 9.9 Hz, 1 H), 5.21 (t, J = 9.3 Hz, 1 H), 5.31 (t, J = 9.3 Hz, 1 H), 7.13–7.19 (m, 3 H), 6.37 (ddd, J =10.2, 3.6, 0.6 Hz, 1 H), 7.18 (br s, 2 H), 7.21 (br s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.52, 20.74, 20.77, 20.89, 40.40, 40.46, 60.42, 62.40, 68.58, 72.58, 74.31, 76.15, 80.25, 122.96, 124.12, 126.05, 134.98, 140.15, 140.67, 168.73, 169.33, 170.21, 170.58, 171.69, 171.73; MS (FAB): m/z (%): 565 (55) [MH+], 505 (42) $[M^+ - OAc]$, 473 (100) $[M^+ - HOMe - OAc]$; EA calcd (%) for C₂₇H₃₂O₁₃ (564.54): C 57.44, H 5.71; found: C 57.40, H 5.78.

3ea. Mp. 106.2–107.2 °C; $[a]_{D}^{25} = -74.4$ (c = 1.10, CHCl₃); IR (KBr) 3247, 1734 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.47 (br s, 2 H), 3.40 (dt, J = 7.8, 4.8 Hz, 1 H), 3.57 (s, 4 H), 3.71 (s, 1 H), 3.73 (s, 1 H), 3.74 (s, 6 H), 4.23 (dd, J = 8.4, 2.1 Hz, 1 H), 5.20 (s, 1 H), 6.01 (s, 2 H), 7.16 (d, J = 8.1 Hz, 1 H), 7.16 (d, J = 8.1 Hz, 1 H), 7.20 (s, J = 8.1 Hz, 1 H), 7.21 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 40.33, 40.50, 53.04, 60.36, 62.83, 64.08, 72.39, 73.90, 123.88, 124.07, 127.02, 128.76, 129.86, 137.98, 139.74, 140.04, 171.83; MS (FAB): m/z(%): 361 (100) [M⁺ – H], 303 (71) [M⁺ – CO₂Me]; EA calcd (%) for C₁₉H₂₂O₇ (362.57): C 62.97, H 6.12; found: C 62.96, H 6.13.

3fa. Oil; $[a]_{25}^{25} = -201.9$ (c = 1.00, CHCl₃); IR (neat) 3431, 1728 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 1.90 (br s, 2 H), 3.54–3.60 (m, 1 H), 3.59 (s, 2 H), 3.54–3.60 (m, 1 H), 3.60 (s, 2 H), 3.74 (s, 6 H), 3.75–3.82 (m, 1 H), 3.98–4.01 (m, 1 H), 4.50–4.57 (m, 1 H), 4.87 (s, 1 H), 5.92 (dd, J = 10.2, 3.0 Hz, 1 H), 6.20–6.26 (m, 1 H), 7.20 (s, 2 H), 7.29 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 40.32, 40.54, 52.97, 60.34, 61.65, 64.52, 73.42, 75.03, 122.28, 123.94, 125.17, 128.15, 128.76, 137.11, 139.20, 139.95, 171.79; MS (FAB): m/z (%): 361 (33) [M⁺ – H], 345 (71) [M⁺ – OH]; EA calcd (%) for C₁₉H₂₂O₇ (362.57): C 62.97, H 6.12; found: C 62.97, H 6.11.

3ga. Oil; $[a]_D^{25} = +5.2$ (c = 1.05, CHCl₃); IR (CHCl₃) 1706, 1362 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 1.90 (ddd, J = 13.2, 10.8, 6.0 Hz, 1 H), 2.33 (ddd, J = 13.2, 5.4, 1.2 Hz, 1 H), 3.56 (s, 4 H), 3.58 (dd, J = 9.9, 5.4 Hz, 1 H), 3.74 (s, 6 H), 3.67

(dd, J = 9.9, 4.5 Hz, 1 H), 4.14–4.17 (m, 1 H), 4.28 (ddd, J = 5.3, 4.8, 2.4 Hz, 1 H), 4.56 (s, 2 H), 4.60 (s, 2 H), 5.09 (dd, J = 10.8, 5.1 Hz, 1 H), 7.13–7.14 (m, 3 H), 7.21 (s, 1 H), 7.29–7.38 (m, 10 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 40.26, 40.45, 41.19, 52.87, 60.37, 70.90, 71.04, 73.32, 80.32, 81.47, 83.65, 121.74, 123.78, 125.00, 127.38, 127.45, 127.48, 128.16, 128.20, 137.89, 137.99, 139.05, 139.84, 140.34, 171.73, 171.76; MS (EI): m/z (%): 361 (9) [M⁺], 439 (100) [M⁺ – CH₂Ph], 439 (100) [M⁺ – H – CH₂Ph – CO₂Me]; EA calcd (%) for C₃₂H₃₄O₇ (530.61): C 72.43, H 6.46; found: C 72.44, H 6.45.

5aa. Mp. 121.6–122.0 °C; $[a]_{D}^{25} = -94.9$ (c = 0.05, CHCl₃); IR (CHCl₃) 1739, 1676, 1234 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.11 (s, 3 H), 2.15 (s, 3 H), 3.88 (ddd, J = 6.9, 6.0, 3.0 Hz, 1 H), 4.17 (dd, J = 12.0, 3.0 Hz, 1 H), 4.31 (dd, J = 12.0, 6.9 Hz, 2 H), 5.28–5.33 (m, 1 H), 5.46–5.49 (m, 1 H), 6.07 (ddd, J = 10.5, 3.0, 2.1 Hz, 1 H), 6.29 (ddd, J = 10.5, 3.0, 1.8 Hz, 1 H), 7.81 (d, J = 3.3 Hz, 1 H), 7.83 (d, J = 3.3 Hz, 1 H), 7.87 (ddd, J =7.8, 2.0, 0.5 Hz, 1 H), 8.31–8.37 (m, 4 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.84, 21.06, 62.82, 64.71, 70.19, 72.73, 125.71, 125.77, 127.08, 127.09, 127.57, 130.17, 132.73, 132.87, 133.25, 133.29, 133.48, 134.02, 134.05, 145.78, 170.15, 170.60, 182.46, 182.59; MS (FAB): m/z (%): 421 (66) [MH⁺], 361 (66) [M⁺ – OAc], 301 (100) [M⁺ – H – 2OAc]; EA calcd (%) for C₂₄H₂₀O₇ (420.41): C 68.57, H 4.80; found: C 68.33, H 5.04.

5ab. Mp. 153.7–154.7 °C; $[a]_{D}^{25} = +25.1$ (c = 1.01, CHCl₃); IR (CHCl₃) 1739, 1668, 1251 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.04 (s, 3 H), 2.12 (s, 3 H), 2.80 (s, 6 H), 3.86 (dt, J =6.6, 3.3 Hz, 1 H), 4.51 (dd, J = 12.3, 3.3 Hz, 1 H), 4.31 (dd, J = 12.0, 6.9 Hz, 1 H), 5.27 (ddd, J = 6.6, 2.0 Hz, 1 H), 5.66 (s, 1 H), 6.13–6.14 (m, 2 H), 7.53 (s, 1 H), 7.70–7.76 (m, 2 H), 8.12–8.17 (m, 2 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 17.52, 20.81, 21.10, 23.91, 62.45, 64.77, 70.03, 70.14, 125.71, 126.12, 126.30, 131.04, 132.35, 133.17, 133.33, 133.68, 134.41, 134.54, 136.94, 138.87, 139.59, 142.82, 170.14, 170.46, 185.27, 186.26; MS (FAB): m/z (%): 449 (100) [MH⁺], 389 (50) [M⁺ – OAc], 329 (70) [M⁺ – H – 2OAc]; EA calcd (%) for C₂₆H₂₄O₇ (448.46): C 69.63, H 5.39; found: C 69.97, H 5.36.

meta-7. Oil; $[a]_{D}^{28} = -11.6$ (c = 1.08, CHCl₃); IR (CHCl₃) 1734, 1246 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.08 (s, 3 H), 2.09 (s, 3 H), 2.26 (s, 3 H), 3.51 (s, 2 H), 3.75 (s, 6 H), 3.74 (s, 3 H), 3.84 (ddd, J = 7.1, 6.0, 3.0 Hz, 1 H), 4.08 (dd, J =12.0, 3.0 Hz, 1 H), 4.27 (dd, J = 12.0, 6.0 Hz, 1 H), 5.23–5.30 (m, 2 H), 5.96 (ddd, J = 10.5, 2.7, 2.1 Hz, 1 H), 6.14 (ddd, J =10.5, 3.0, 1.8 Hz, 1 H), 7.02 (s, 1 H), 7.05 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 19.11, 20.87, 21.13, 39.28, 40.74, 53.00, 59.84, 62.85, 65.00, 69.35, 73.55, 120.92, 124.52, 127.52, 131.66, 133.69, 137.91, 138.76, 139.84, 170.24, 170.59, 171.89; MS (FAB): m/z (%): 459 (29) [M⁺ – H], 399 (34) [M⁺ – H – HOAc], 341 (100) [M⁺ – H – 2OAc]; EA calcd (%) for C₂₄H₂₈O₉ (460.47): C 62.60, H 6.13; found: C 62.67, H 6.12.

*meta-***9a.** Oil; $[a]_{D}^{24} = +36.9$ (c = 1.15, CHCl₃); IR (CHCl₃) 1733, 1248 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 0.92 (t, J = 7.5 Hz, 3 H), 1.34 (sext, J = 7.5 Hz, 2 H), 1.51–1.61 (m, 2 H), 2.07 (s, 3 H), 2.09 (s, 3 H), 2.56 (t, J = 7.8 Hz, 2 H), 3.57 (s, 2 H), 3.66 (d, J = 1.5 Hz, 2 H), 3.73 (s, 3 H), 3.74 (s, 3 H), 3.85 (dt, J = 6.6, 3.6 Hz, 1 H), 4.07 (dd, J = 12.0, 3.6 Hz, 1 H), 4.27 (dd, J = 12.0, 6.3 Hz, 1 H), 5.23–5.27 (m, 1 H), 5.30 (dd, J = 4.5, 2.1 Hz, 1 H), 6.02 (ddd, J = 10.5, 3.0, 2.1 Hz, 1 H), 6.15 (ddd, J = 10.5, 2.7, 1.5 Hz, 1 H), 6.92 (s, 1 H), 7.00 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 13.98, 20.81, 21.03, 22.44, 33.79, 35.48, 39.06, 40.39, 52.86, 52.89, 60.13, 62.54, 64.86, 69.76, 71.80, 124.12, 124.51, 126.59, 131.47, 133.69, 136.74, 140.71, 141.72, 170.23, 170.56, 171.77, 171.91; MS (FAB): m/z (%): 503 (13) [MH⁺], 443 (100) [M⁺ – OAc], 382 (94) [M⁺ – 2HOAc]; EA calcd (%) for C₂₇H₃₄O₉ (502.55): C 64.53, H 6.82; found: C 64.52, H 6.83.

meta-9b. Oil; $[a]_{24}^{D4} = -18.0 (c = 1.35, CHCl_3)$; IR (CHCl₃) 1734, 1244 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.07 (s, 3 H), 2.08 (s, 3 H), 3.67 (s, 2 H), 3.74 (s, 2 H), 3.76 (s, 3 H), 3.77 (s, 3 H), 3.88 (dt, J = 6.3, 3.3 Hz, 1 H), 4.06–4.12 (m, 1 H), 4.28 (dd, J = 12.0, 6.6 Hz, 1 H), 5.25–5.30 (m, 1 H), 5.40 (dd, J = 4.8, 2.1 Hz, 1 H), 6.06 (ddd, J = 10.5, 3.0, 2.1 Hz, 1 H), 6.22 (ddd, J = 10.5, 3.0, 1.5 Hz, 1 H), 7.31–7.46 (m, 5 H), 7.53–7.56 (m, 2 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.79, 21.00, 39.15, 40.44, 52.94, 52.96, 60.15, 62.57, 64.81, 69.74, 71.79, 122.95, 125.01, 125.49, 126.98, 127.09, 128.54, 131.03, 134.48, 138.72, 140.23, 140.75, 141.37, 170.19, 170.54, 171.61, 171.78; MS (FAB): m/z (%): 523 (19) [MH⁺], 463 (88) [M⁺ – OAc], 402 (100) [M⁺ – 2HOAc]; EA calcd (%) for C₂₉H₃₀O₉ (522.54): C 66.66, H 5.79; found: C 66.57, H 5.88.

10aa. Mp. 52.3–53.0 °C; $[a]_{D}^{25} = +35.6 (c = 1.07, CHCl_3)$; IR (CHCl₃) 1735, 1240 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.06 (s, 3 H), 2.07 (s, 3 H), 2.08 (s, 3 H), 2.09 (s, 3 H), 3.60 (s, 2 H), 3.70 (d, J = 2.7 Hz, 2 H), 3.73 (s, 3 H), 3.75 (s, 3 H), 3.81–3.89 (m, 2 H), 4.08 (dt, J = 12.3, 2.7 Hz, 2 H), 4.27 (dd, J = 12.0, 6.6 Hz, 1 H), 4.30 (dd, J = 12.0, 5.7 Hz, 1 H), 5.22–5.33 (m, 4 H), 5.98 (ddd, J = 10.2, 2.4, 1.8 Hz, 1 H), 6.04 (ddd, J =10.5, 3.3, 1.8 Hz, 1 H), 6.15 (ddd, J = 10.5, 2.6, 1.5 Hz, 1 H), 7.14 (s, 1 H), 7.24 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.80, 20.84, 20.99, 21.09, 39.20, 40.40, 52.97, 52.99, 60.12, 62.45, 62.63, 64.76, 64.80, 69.56, 70.02, 71.64, 73.30, 123.50, 124.59, 124.79, 126.15, 131.06, 131.44, 134.43, 137.92, 139.79, 141.23, 170.19, 170.25, 170.57, 171.58, 171.75; MS (EI): m/z (%): 657 (35) $[M^+ - H]$, 599 (45) $[M^+ - H - OAc]$, 539 (100) $[M^+ - H - 2OAc], 479 (92) [M^+ - 2H - 3OAc]; EA calcd (\%)$ for C₃₃H₃₈O₁₄ (658.65): C 60.18, H 5.82; found: C 60.10, H 5.90.

10ab. Mp. 57.7–58.3 °C; $[a]_{D}^{28} = -6.3$ (c = 1.00, CHCl₃); IR (CHCl₃) 1737, 1241 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.06 (s, 3 H), 2.07 (s, 3 H), 2.08 (s, 3 H), 2.17 (s, 3 H), 2.40 (s, 3 H), 3.81 (dt, J = 6, 3.6 Hz, 1 H), 3.93 (dt, J = 7.5, 4.2 Hz, 1 H), 4.27 (dd, J = 12.0, 6.0 Hz, 1 H), 4.28 (dd, J = 12.0, 8.1 Hz)1 H), 4.56 (d, J = 14.1 Hz, 1 H), 4.62 (d, J = 14.1 Hz, 1 H), 4.70(d, J = 14.7 Hz, 1 H), 4.82 (d, J = 14.7 Hz, 1 H), 5.16-5.28 (m, J = 14.7 Hz, 1 Hz), 5.16-5.28 (m, J = 14.7 Hz, 1 Hz), 5.16-5.28 (m, J = 14.7 Hz), 5.16-4 H), 5.96–6.12 (m, 4 H), 7.15 (s, 1 H), 7.20 (s, 1 H), 7.31 (d, J = 7.8 Hz, 2 H), 7.75 (d, J = 7.81 Hz, 2 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): *δ* 20.84, 21.03, 21.08, 21.53, 52.83, 53.27, 61.87, 62.54, 64.22, 64.66, 69.74, 71.10, 71.56, 72.89, 121.76, 124.23, 124.92, 126.71, 127.41, 129.68, 130.87, 131.03, 135.81, 137.76, 139.14, 143.56, 170.11, 170.43, 170.48, 170.53; MS (EI): m/z (%): 696 (100) [M+ – H], 638 (50) [M+ – OAc]; EA calcd (%) for C35H39NO12S (697.75): C 60.25, H 5.63, N 2.01; found: C 60.43, H 5.66, N 1.80.

10ac. Mp. 46.2–47.2 °C; $[a]_{D}^{25} = +10.2 (c = 1.05, CHCl_3)$; IR (CHCl₃) 1738, 1228 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.07 (s, 3 H), 2.08 (s, 3 H), 2.09 (s, 3 H), 2.10 (s, 3 H), 3.87 (dt, J = 6.6, 3.3 Hz, 1 H), 3.89 (dt, J = 6.9, 3.3 Hz, 1 H), 4.09 (dd, J =12.0, 3.3 Hz, 2 H), 4.29 (dd, J = 12.0, 5.7 Hz, 1 H), 4.31 (dd, J = 12.0, 4.5 Hz, 1 H), 5.10 (br s, 2 H), 5.16–5.34 (m, 6 H), 6.01 (ddd, *J* = 7.2, 2.7, 1.8 Hz, 1 H), 6.03 (ddd, *J* = 7.8, 3.3, 2.1 Hz, 1 H), 6.14 (ddd, J = 7.8, 2.7, 1.2 Hz, 1 H), 6.17 (ddd, J = 8.1, 2.7, 1.2 Hz, 1 H), 7.20 (s, 1 H), 7.28 (s, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.84, 20.87, 21.07, 21.12, 62.27, 62.65, 64.59, 64.78, 69.61, 70.58, 71.92, 72.79, 73.08, 73.21, 120.20, 124.62, 124.89, 126.44, 130.93, 131.25, 132.88, 138.60, 138.71, 140.72, 170.16, 170.20, 170.46, 170.52; MS (EI): m/z (%): 543 (100) $[M^+ - H]$, 485 (16) $[M^+ - OAc]$, 425 (15) $[M^+ - H - 2OAc]$; EA calcd (%) for C₂₈H₃₂O₁₁ (544.55): C 61.76, H 5.92; found: C 61.78, H 5.90.

10ga. Oil; $[a]_{2}^{D} = +18.0 (c = 1.35, CHCl_3)$; IR (CHCl_3) 1734, 1246 cm⁻¹; ¹H NMR (300 MHz, CDCl_3, 25 °C): δ 1.92 (ddd, J =13.2, 10.8, 6.0 Hz, 1 H), 2.06 (s, 3 H), 2.07 (s, 3 H), 3.57 (d, J =2.1 Hz, 2 H), 3.58 (dd, J = 10.2, 5.4 Hz, 1 H), 3.67 (s. 2 H), 3.68 (dd, J = 13.8, 4.5 Hz, 1 H), 3.73 (s, 3 H), 3.75 (s, 3 H), 3.83 (dt, J = 6.3, 3.6 Hz, 1 H), 4.06 (dd, J = 12.0, 3.0 Hz, 1 H), 4.16–4.19 (m. 1 H), 4.26 (dd, J = 12.0, 6.3 Hz, 1 H), 4.28–4.31 (m, 1 H), 4.56 (s, 2 H), 4.60 (s, 2 H), 5.10 (dd, J = 10.8, 5.1 Hz, 1 H), 5.22–5.26 (m, 1 H), 5.29–5.31 (m, 1 H), 5.98 (ddd, J = 10.5, 2.8, 2.1 Hz, 1 H), 6.10 (ddd, J = 10.5, 2.7, 1.2 Hz, 1 H), 7.10 (s, 1 H), 7.23 (s, 1 H), 7.29–7.36 (m, 10 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.73, 20.94, 39.09, 40.32, 41.15, 52.82, 52.85, 60.11, 62.43, 64.71, 69.70, 70.88, 70.97, 71.64, 73.30, 80.23, 81.41, 83.69, 121.79, 124.60, 124.71, 127.24, 127.40, 127.45, 128.13, 128.19, 131.09, 133.87, 137.78, 137.92, 139.05, 140.35, 140.92, 170.12, 170.45, 171.59, 171.66; MS (EI): m/z (%): 741 (100) [M⁺ – H], 683 (28) [M⁺ – OAc], 651 (12) [M⁺ – CH₂Ph], 623 (15) [M⁺ – H – 2OAc]; EA calcd (%) for C₄₂H₄₆O₁₂ (742.81): C 67.91, H 6.24; found: C 67.89, H 6.26.

12a. Mp. 83.1–84.1 °C; $[a]_{D}^{24} = +59.9 (c = 0.98, CHCl_3)$; IR (CHCl₃) 1735, 1244 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.06 (s, 6 H), 2.08 (s, 6 H), 3.71 (s, 2 H), 3.74 (s, 6 H), 3.75 (s, 2 H), 3.81 (dt, J = 6.3, 3.3 Hz, 2 H), 4.04 (dd, J = 12.0, 3.6 Hz, 2 H), 4.26 (dd, J = 12.0, 6.0 Hz, 2 H), 5.24–5.28 (m, 2 H), 5.33 (dd, J = 4.5, 2.1 Hz, 2 H), 6.03 (ddd, J = 10.2, 2.7, 1.8 Hz, 2 H), 6.13 (ddd, J = 10.2, 2.7, 0.9 Hz, 2 H), 7.14 (s, 2 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.86, 21.06, 39.26, 52.97, 62.51, 64.76, 64.80, 69.72, 71.61, 124.95, 126.44, 131.01, 134.36, 140.77, 170.22, 170.60, 171.73; MS (EI): m/z (%): 658 (56) [M⁺], 599 (100) [M⁺ – OAc], 539 (33) [M⁺ – H – 2OAc]; EA calcd (%) for C₃₃H₃₈O₁₄ (658.65): C 60.18, H 5.82; found: C 60.22, H 5.77.

12b. Oil; $[a]_{D}^{20} = +38.4$ (c = 1.05, CHCl₃); IR (CHCl₃) 1737, 1236 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.07 (s, 6 H), 2.09 (s, 6 H), 3.84 (dt, J = 6.6, 2.7 Hz, 2 H), 4.06 (dd, J = 12.0, 3.6 Hz, 2 H), 4.27 (dd, J = 12.0, 6.9 Hz, 2 H), 5.15–5.31 (m, 8 H), 6.03 (ddd, J = 10.5, 3.0, 1.2 Hz, 2 H), 6.13 (ddd, J = 10.5, 2.4, 1.2 Hz, 2 H), 7.18 (s, 2 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.90, 21.12, 62.37, 64.68, 70.23, 71.83, 72.67, 124.88, 126.84, 130.04, 132.66, 139.81, 170.16, 170.23, 170.55; MS (EI): m/z (%): 544 (40) [M⁺], 484 (37) [M⁺ – H – OAc], 425 (100) [M⁺ – H – 2OAc]; EA calcd (%) for C₂₈H₃₂O₁₁ (544.55): C 61.76, H 5.92; found: C 61.73, H 5.92.

14a. Oil; $[a]_{D}^{25} = -30.4$ (c = 1.00, CHCl₃); IR (CHCl₃) 1733, 1259 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 1.19 (t, J = 6.9 Hz, 3 H), 1.22 (t, J = 7.5 Hz, 3 H), 2.03 (s, 3 H), 2.05 (s, 3 H), 2.05–2.15 (m, 2 H), 2.43 (t, J = 7.5 Hz, 2 H), 3.53 (t, *J* = 7.5 Hz, 1 H), 3.75–3.81 (m, 1 H), 4.03 (dd, *J* = 12.0, 3.0 Hz, 1 H), 4.03 (dd, J = 12.0, 6.0 Hz, 1 H), 4.06 (q, J = 7.2 Hz, 2 H), 4.12 (s, 4 H), 4.14 (q, J = 7.2 Hz, 2 H), 4.22 (dd, J = 12.0, 6.0 Hz, 1 H), 5.24–5.30 (m, 2 H), 5.94 (d, J = 10.5 Hz, 1 H), 6.12 (dd, J = 10.5 1.2 Hz, 1 H), 7.15 (d, J = 8.4 Hz, 1 H), 7.20 (s, 1 H), 7.21 (d, J = 8.4 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 14.21, 14.38, 20.83, 21.08, 25.90, 30.73, 54.91, 55.05, 60.39, 60.53, 62.80, 63.11, 64.92, 68.96, 73.63, 121.84, 122.21, 124.83, 126.62, 131.32, 137.32, 139.21, 139.41, 170.18, 170.55, 171.85, 172.78; MS (FAB): m/z (%): 518 (100) [MH+], 444 (25) $[M^+ - CO_2Et]$; EA calcd (%) for $C_{27}H_{35}NO_9$ (517.57): C 62.66, H 6.82, N 2.71; found: C 62.76, H 7.00, N 2.43.

14b. Oil; $[a]_{27}^{27} = -128.3$ (c = 1.22, CHCl₃); IR (CHCl₃) 1736, 1239 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.06 (s, 3 H), 2.08 (s, 3 H), 3.12 (dd, J = 13.5, 7.0 Hz, 1 H), 3.18 (dd, J = 13.5, 8.0 Hz, 1 H), 3.60 (s, 3 H), 3.77–3.86 (m, 2 H), 4.06 (dd, J = 12.0, 3.0 Hz, 1 H), 4.15 (d, J = 11.7 Hz, 2 H), 4.26 (dd, J = 11.7, 5.7 Hz, 1 H), 4.27 (d, J = 11.7 Hz, 2 H), 5.28–5.32 (m, 2 H), 5.97 (dt, J = 10.5, 1.8 Hz, 1 H), 6.15 (ddd, J = 10.5, 2.7, 1.2 Hz, 1 H), 7.18–7.31 (m, 8 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.82, 21.06, 37.27, 51.29, 55.14, 55.24, 62.79, 64.93, 66.22, 68.95, 73.63, 121.86, 122.21, 124.84, 126.40, 126.59, 128.23, 128.75, 131.31, 137.29, 137.51, 139.30, 139.52, 170.17, 170.53, 172.23; MS (FAB): m/z (%): 494 (100) [MH⁺], 434 (17) [M⁺ – OAc], 402 (27) [M⁺ – CH₂Ph]; EA calcd (%) for C₂₈H₃₁NO₇ (493.55): C 68.14, H 6.33, N 2.84; found: C 68.17, H 6.22, N 2.92. **14c.** Oil; $[a]_D^{27} = -24.7$ (c = 1.13, CHCl₃); IR (CHCl₃) 1736, 1239 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 0.94 (d, J = 6.0 Hz, 3 H), 0.97 (d, J = 6.3 Hz, 3 H), 1.64–1.77 (m, 3 H), 2.07 (s, 3 H), 2.08 (s, 3 H), 3.62 (t, J = 7.8 Hz, 1 H), 3.70 (s, 3 H), 3.80 (ddd, J = 7.0, 5.7, 3.0 Hz, 1 H), 4.05 (dd, J = 12.0, 3.0 Hz, 1 H), 4.07 (d, J = 11.4 Hz, 2 H), 4.19–4.24 (m, 2 H), 4.25 (dd, J = 12.0, 5.7 Hz, 1 H), 5.28–5.33 (m, 2 H), 5.97 (dt, J = 10.2, 1.8 Hz, 1 H), 6.15 (ddd, J = 10.5, 3.0, 1.5 Hz, 1 H), 7.19 (d, J = 8.1 Hz, 1 H), 7.23–7.25 (m, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.88, 21.13, 22.48, 22.78, 25.07, 39.99, 51.27, 54.81, 54.95, 62.05, 62.87, 64.99, 68.91, 73.76, 121.94, 122.26, 124.91, 126.58, 131.37, 137.19, 139.60, 139.80, 170.23, 170.61, 173.60; MS (FAB): m/z (%): 460 (100) [MH⁺], 400 (32) [M⁺ - OAc]; EA calcd (%) for C₂₅H₃₃NO₇ (459.53): C 65.34, H 7.24, N 3.05; found: C 65.42, H 6.97, N 3.23.

Representative procedure for preparation of *C*-arylglycosyldiynes: synthesis of diyne 8a

To a solution of 4,4-dimethoxycarbonyl-1-trimethylsilylhept-1,6-diyne (1.95 g, 7.0 mmol) and SnCl₄ (912 mg, 3.5 mmol) in dry CH₂Cl₂ (10 mL) was added dropwise a solution of tri-Oacetyl-D-glucal (955 mg, 3.5 mmol) in CH₂Cl₂ (40 mL) and the reaction mixture was stirred for overnight at room temperature. the reaction mixture was poured into 10% potassium sodium tartrate (70 mL), and stirred for 3 h. The aqueous layer was extracted with CH_2Cl_2 (20 mL \times 3). The combined organic layers were washed with sat. NaHCO₃ and brine (each 20 mL), dried over Mg₂SO₄, and concentrated in vacuo. The residue was purified by silica gel column flush chromatography (eluent, hexane : AcOEt = $6: 1 \sim 3: 1$) to afford the recovered divide (548.5 mg, 28%) and then 8a (961.7 mg, 65% based on the glucal) as pale yellow oil; $[a]_{D}^{30} = -28.5$ (c = 1.05, CHCl₃); IR (CHCl₃) 3307, 2260, 1739, 1234 cm⁻¹; ¹H NMR (300 MHz, $CDCl_3$, 25 °C): δ 2.03 (t, J = 2.7 Hz, 1 H), 2.09 (s, 3 H), 2.12 (s, 3 H), 2.97 (d, J = 2.7 Hz, 2 H), 3.04 (d, J = 2.1 Hz, 2 H), 3.76 (s, 6 H), 4.03 (dt, J = 9.0, 3.9 Hz, 1 H), 4.22 (d, J = 4.2 Hz, 2 H), 4.90–4.93 (m, 1 H), 5.27 (ddd, J = 9.0, 3.9, 1.8 Hz, 1 H), 5.74 (dt, J = 10.2, 1.8 Hz, 1 H), 5.84 (ddd, J =10.2, 3.6, 1.8 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.79, 21.01, 22.76, 23.02, 53.08, 56.49, 63.00, 63.84, 64.68, 69.73, 71.79, 78.15, 79.36, 81.36, 125.14, 129.11, 168.70, 169.99, 170.63; MS (FAB): m/z (%): 421 (53) [MH⁺], 376 (29) [M⁺ – H - Ac], 361 (100) [M⁺ - OAc], 301 (71) [M⁺ - H - 2OAc]; EA calcd (%) for C₂₁H₂₄O₉ (420.41): C 59.99, H 5.75; found: C 59.95, H 5.79.

8b. Oil; $[a]_{D}^{2b} = -22.1$ (c = 1.05, CHCl₃); IR (CHCl₃) 3306, 2253, 1740, 1240 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.09 (s, 3 H), 2.10 (s, 3 H), 2.13 (t, J = 2.4 Hz, 1 H), 2.43 (s, 3 H), 3.95 (dt, J = 9.0, 3.9 Hz, 1 H), 4.14 (d, J = 2.4 Hz, 2 H), 4.19 (d, J = 4.2 Hz, 2 H), 4.21 (d, J = 1.8 Hz, 2 H), 4.80–4.83 (m, 1 H), 5.25 (ddd, J = 9.0, 3.6, 1.8 Hz, 1 H), 5.69 (ddd, J = 10.2, 3.0, 1.5 Hz, 1 H), 5.75 (dt, J = 9.9, 1.5 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.72, 20.93, 21.50, 36.24, 36.45, 62.79, 63.55, 64.43, 69.84, 74.06, 75.98, 79.16, 81.52, 125.46, 127.61, 128.24, 129.34, 134.87, 143.70, 169.86, 170.45; MS (FAB): m/z (%): 460 (24) [MH⁺], 400 (100) [M⁺ – OAc], 340 (20) [M⁺ – H – 2OAc]; EA calcd (%) for C₂₃H₂₅NO₇S (459.51): C 60.12, H 5.48, N 3.05; found: C 60.42, H 5.39, N 2.84.

8c. Oil; $[a]_{D}^{23} = -31.6$ (c = 1.15, CHCl₃); IR (CHCl₃) 3306, 2120, 1740, 1236 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.07 (s, 3 H), 2.08 (s, 3 H), 2.46 (t, J = 2.4 Hz, 1 H), 4.07 (dt, J = 9.0, 3.9 Hz, 1 H), 4.21 (d, J = 3.9 Hz, 2 H), 4.23 (d, J = 2.4 Hz, 2 H), 4.30 (d, J = 1.8 Hz, 2 H), 4.98–5.02 (m, 1 H), 5.27 (ddd, J = 9.0, 3.6, 1.8 Hz, 1 H), 5.77 (dt, J = 10.2, 1.8 Hz, 1 H), 5.87 (ddd, J = 10.2, 3.6, 1.8 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.87, 21.05, 56.49, 56.67, 62.91, 63.83, 64.55, 69.91, 75.14, 78.62, 81.82, 82.63, 125.52, 128.63, 170.02, 170.62; MS

(FAB): m/z (%): 307 (100) [MH⁺]; EA calcd (%) for C₁₆H₁₈O₆ (306.31): C 62.74, H 5.92; found: C 60.72, H 5.94.

11a. Oil; $[a]_{25}^{25} = -30.3$ (c = 1.05, CHCl₃); IR (CHCl₃) 1740, 1235 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.08 (s, 6 H), 2.10 (s, 6 H), 2.98 (s, 2 H), 2.99 (s, 2 H), 3.74 (s, 6 H), 4.00 (dt, J = 9.0, 4.2 Hz, 2 H), 4.20 (d, J = 3.6 Hz, 4 H), 4.89–4.92 (m, 2 H), 5.26 (ddd, J = 9.0, 3.6, 1.8 Hz, 2 H), 5.73 (dt, J = 10.2, 1.8 Hz, 2 H), 5.82 (ddd, J = 10.2, 3.3, 1.8 Hz, 2 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.87, 21.08, 23.20, 53.13, 56.70, 63.01, 63.88, 64.70, 69.78, 79.50, 81.36, 125.27, 129.09, 168.70, 170.02, 170.66; MS (FAB): m/z (%): 633 (100) [MH⁺], 573 (99) [M⁺ - OAc]; EA calcd (%) for C₃₁H₃₆O₁₄ (632.61): C 58.86, H 5.74; found: C 59.85, H 5.75.

11b. Mp. 103.8–104.5 °C; $[a]_{20}^{20} = -109.6$ (c = 1.05, CHCl₃); IR (CHCl₃) 1739, 1238 cm⁻¹; ¹H NMR (300 MHz, CDCl₃, 25 °C): δ 2.09 (s, 6 H), 2.10 (s, 6 H), 4.07 (dd, J = 9.0, 4.8 Hz, 2 H), 4.23 (s, 2 H), 4.24 (d, J = 1.5 Hz, 2 H), 4.29 (d, J = 1.5 Hz, 2 H), 5.00–5.04 (m, 2 H), 5.30 (ddd, J = 9.0, 3.6, 1.8 Hz, 2 H), 5.79 (dt, J = 10.2, 1.5 Hz, 2 H), 5.88 (ddd, J = 10.2, 3.3, 2.1 Hz, 2 H); ¹³C NMR (75 MHz, CDCl₃, 25 °C): δ 20.55, 20.73, 56.46, 62.57, 63.49, 64.24, 69.64, 76.38, 81.48, 82.43, 125.27, 128.31, 169.66, 170.22; MS (FAB): m/z (%): 519 (49) [MH⁺], 459 (100) [M⁺ – OAc], 399 (6) [M⁺ – H – 2OAc]; EA calcd (%) for C₂₆H₃₀O₁₁ (518.51): C 60.23, H 5.83; found: C 60.22, H 5.83.

Acknowledgements

We gratefully acknowledge financial support from the Naito Research Grant.

References

- G. D. Daves, Jr., Acc. Chem. Res., 1990, 23, 201; M. H. Postema, Tetrahedron, 1992, 48, 8545; Y. Du, R. J. Linhardt and I. R. Vlahov, Tetrahedron, 1998, 54, 9913; H. Togo, W. He, Y. Waki and M. Yokoyama, Synlett, 1998, 700; M. Isobe, R. Nishizawa, S. Hosokawa and T. Nishikawa, Chem. Commun., 1998, 2665; I. P. Smoliakova, Curr. Org. Chem., 2000, 4, 589; L. Somsák, Chem. Rev., 2001, 101, 81; C. Taillefumier and Y. Chapleur, Chem. Rev., 2004, 104, 263.
- 2 C. Jaramillo and S. Knapp, Synthesis, 1994, 1.
- 3 J. Rohr and R. Thiericke, *Nat. Prod. Rep.*, 1992, 103; M. C. Carreño and A. Urbano, *Synlett*, 2005, 1.
- 4 K. Suzuki, Pure Appl. Chem., 1994, 66, 2175.
- 5 K. A. Parker and Y.-h. Koh, J. Am. Chem. Soc., 1994, 116, 11149; D. E. Kaelin, Jr., O. D. Lopez and S. F. Martin, J. Am. Chem. Soc., 2001, 123, 6937; D. E. Kaelin, Jr., S. M. Sparks, H. R. Plake and S. F. Martin, J. Am. Chem. Soc., 2003, 125, 12994.
- 6 S. R. Pully and J. P. Carey, J. Org. Chem., 1998, 63, 5275; D. Paetsch and K. H. Dötz, *Tetrahedron Lett.*, 1999, 40, 487; E. Janes, M. Nieger, P. Saarenketo and K. H. Dötz, *Eur. J. Org. Chem.*, 2003, 2276; C. Fuganti and S. Serra, *Synlett*, 1999, 1241; E. Brenna, C. Fuganti, P. Grasselli, S. Serra and S. Zambotti, *Chem. Eur. J.*, 2002, 8, 1872; R. R. Schmidt and G. Effenberger, *Liebigs Ann. Chem.*, 1987, 825.
- 7 F. E. McDonald, H. Y. H. Zhu and C. R. Holmquist, J. Am. Chem. Soc., 1995, 117, 6605.
- 8 Y. Yamamoto, R. Ogawa and K. Itoh, *Chem. Commun.*, 2000, 549; Y. Yamamoto, T. Arakawa, R. Ogawa and K. Itoh, *J. Am. Chem. Soc.*, 2003, **125**, 12143; Y. Yamamoto, K. Kinpara, T. Saigoku, H. Nishiyama and K. Itoh, *Org. Biomol. Chem.*, 2004, **2**, 1287.
- 9 Y. Yamamoto, T. Saigoku, T. Ohgai, H. Nishiyama and K. Itoh, *Chem. Commun.*, 2004, 2702.
- 10 Y. Ichikawa, M. Isobe, M. Konobe and T. Goto, *Carbohydr. Res.*, 1992, **33**, 7911.
- 11 E. Müller, A. Scheller, W. Winter, F. Wagner and H. Meier, *Chem. Ztg.*, 1975, **99**, 155; R. L. Hillard III and K. P. C. Vollhardt, *J. Am. Chem. Soc.*, 1977, **99**, 4058.
- 12 Y. Yamamoto, K. Hata, T. Arakawa and K. Itoh, *Chem. Commun.*, 2003, 1290.
- 13 J. Xu, A. Egger, B. Bernet and A. Vasella, *Helv. Chim. Acta*, 1996, **79**, 2004.

- 14 T. Tsukiyama and M. Isobe, Tetrahedron Lett., 1992, 33, 7911.
- 15 M. Takase, T. Morikawa, H. Abe and M. Inouye, *Org. Lett.*, 2003, 5, 625.
- 16 N. C. Chaudhuri, R. X.-F. Ren and E. T. Kool, *Synlett*, 1997, 341; E. T. Kool, J. C. Morales and K. M. Guckian, *Angew. Chem., Int. Ed.*, 2000, **39**, 990; E. T. Kool, *Acc. Chem. Res.*, 2002, **35**, 936; Q. Wu and C. Simons, *Synthesis*, 2004, 1533.
- 17 P. Sinaÿ, *Pure Appl. Chem.*, 1997, **69**, 459; L. Liu, M. McKee and H. D. Postema, *Curr. Org. Chem.*, 2001, **5**, 1133.
- 18 R. M. Beesley, C. K. Ingold and J. F. Thorpe, J. Chem. Soc., 1915, 107, 1080; J. Jager, T. Graafland, H. Schenk, A. J. Kirby and J. B. F. N.

Engberts, J. Am. Chem. Soc., 1984, **106**, 139; M. E. Jung, Synlett, 1999, 843; J. Kaneti, A. J. Kirby, A. H. Koedjikov and I. G. Pojarlieff, Org. Biomol. Chem., 2004, **2**, 1098.

- 19 A. Dondoni and A. Marra, Chem. Rev., 2000, 100, 4395.
- S. Kotha and E. Brahmachary, *Tetrahedron Lett.*, 1997, **38**, 3561; S. Kotha, K. Mohanraja and S. Durani, *Chem. Commun.*, 2000, 1909;
 S. Kotha and N. Sreenivasachary, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 1413; S. Kotha and E. Brahmachary, *Bioorg. Med. Chem.*, 2002, **10**, 2291; S. Kotha and E. Brahmachary, *J. Organomet. Chem.*, 2004, **689**, 158.
- 21 N. Oshima, H. Suzuki and Y. Moro-oka, Chem. Lett., 1984, 1161.